The 3rd Annual Cell Line Development & Engineering Asia conference brings together experts and top scientists from pharma/biotech companies, CMOs, leading technology providers and research institutes to discuss current opportunities and challenges, such as quality and titer improvements, best cell culture media design, development and banking, overcoming regulatory hurdles and more.

1. www.celllineasia.com
Produced by: Associate Sponsor: Session Spotlight Sponsors: Exhibitors:
Associations:
REGISTER NOW! Customer Service Hotline: +65 6508 2401 / +86 21 2326 3680
International Marketing Partner:
Media Partners:
20 — 23 May 2014
Grand Hyatt Shanghai, China
Accelerating Your Cell Line Development with Efficacy & Quality
THE 2014 NEW EXPERT FACULTY INCLUDES:
Dr Zhao (David)
Xiao Jian
Senior Vice President &
ChiefTechnologyOfficer,
Wuhan YZY
Biopharma, China
Dr H. Fai Poon
Director, Cell Culture,
Hisun
Pharmaceuticals,
China
Dr Chengbin Wu
Chief Scientific Officer &
President of R&D,
Shanghai CP Guojian
Pharmaceutical, China
Dr Qian Xue Ming
CEO & Chairman,
Mabspace
Biosciences, China
What’s New for 2014?
New & Unpublished Data on Targeted
Integration, Glycosylation, Transient Expression
& Clone Selection
Cell Line Development Strategies for Complex
Biologics
Achieve an Ideal Cell Culture Media for High
Yield & Reproducibility
Navigate the Cell Line Regulatory Landscape
for Your Drug
Innovative Technology Showcase to Accelerate
your Cell Line Development Process
Pre-Conference Workshops: 20 May 2014
Optimizing Cell Culture Media Development & Design
Strategies
Cell Banking Management
Post-Conference Workshop: 23 May 2014
The Road to Commercialization: From Cell to MarketC
B
A
BIOBIO
MANUFACTURING
BIOSIMILARSSIMILARSSIMILARSBIBI
ASIA
BI
Co-located with:
Part of
Bronze Sponsor:
PRODUCTION
BIOPHARMA
DEVELOPMENT &
WEEK
C LL LINEC LL LINEC LL LINE
DEVELOPMENT &
ENGINEERING ASIA
3RD ANNUAL
Life
Sciences

2. REGISTERTODAY! +6565082401/+862123263680 register@ibcasia.com.sg www.celllineasia.com
C LL LINEC LL LINEC LL LINE
DEVELOPMENT &
ENGINEERING ASIA
CONFERENCE DAY ONE
21 MAY 2014 | WEDWEDNESDAY
8:00 Morning Coffee and Registration Opens
8:50 Welcome Address from IBC Asia & Ice Breaker
Exchange Business Cards & Get To Know Industry Peers
9:00 Chairperson’s Opening Remarks
BIOPHARMA VISIONARY KEYNOTE SESSIONS
9:05 Global Biopharma Outlook
• Trends in the global biopharma industry
• Priorities of investment in China and opportunities for growth
• Challenges and opportunities in the Asian region
• The role of Biosimilars in the region’s biopharma industry
• Key criteria to further the development of the sector in China and
Asia
Panelists:
Scott Liu, CEO, Henlius Pharmacueticals, China
Youling Wu, CEO, Zhejiang Teruisi, China
Jianguo Yang, Principal Scientist, Sanofi Genzyme, USA
Jeremy Caudill, Global VP Business Development, Samsung
Biologics, Korea
Abdullah Baaj, CEO, Boston Oncology, USA
Sameer Agarwal, SeniorVicePresident,BusinessCenterStrategic
Marketing, Business Unit Generic Drugs & Standard Solutions,
Fresenius Kabi Deutschland GmbH, Germany
9:50 Biopharma Regulatory Updates & Development
• Clinical approvals for biopharmaceuticals
• Regulatory differences between the FDA/EMA/ICH and local
agencies in China and other emerging markets such as India and
SEA.
• How to demonstrate process consistency and what is required
• Accelerating IND applications
• Updates on Biosimilars guidelines in key Asian markets
Panelists:
Dr Victoria Elegant, Vice President of Medical & Regulatory
Affairs, Baxter, China
Prof. Andrea Laslop, Head of Scientific Office, Austrian Agency
for Food and Health Safety, Austrian Member, European
Medicines Agency, Austria
BIOPHARMA TECHNOLOGY SHOWCASE
10:30 Cutting Edge Solutions & Innovation in Biopharma
If you have leading edge technology and solutions and would like to
showcase your innovation in front of biopharma industry stakeholders,
please contact Yvonne Leong: Yvonne.leong@ibcasia.com.sg
11:00 Morning Networking & Refreshment Break
11:45 Chairperson’s Opening Remarks
Dr Jianguo Yang, Principal Scientist, Genzyme/Sanofi, USA
ENSURING QUALITY AND STABILITY IN
CELL LINE DEVELOPMENT
11:50 Applying Quality by Design (QbD) to Cell Culture
Development
• How to develop a Quality by Design (QbD) strategy in cell line
development
• How to implement QbD in cell line development
• What are the Critical Quality Attributes (CQA) in upstream
processing impact on downstream processing
• What are the CQA requirements on protein glycosylation
• How quality defines the process
Dr Jianguo Yang, Principal Scientist, Genzyme/Sanofi, USA
12:20 Molecular Profiling of Recombinant Protein Quality
Quantity and Quality, both are critical criteria for the success of
recombinant protein expression in cell line development.Whilst some
quality attributes directly determine protein structure and, hence,
function, others can lead to events that have secondary (and potentially
deleterious)effectsto therapeuticefficacy,suchasstability, aggregation
and immunogenicity. I will review profiling technologies (in current
and potential future use) that assess quality of recombinant proteins
and discuss how information and interpretation of 'omics approaches
may be applied to direct/improve/engineer structural quality of specific
products.
Prof. Alan Dickson, Professor of Biotechnology, Director, Centre
of Excellence in Biopharmaceuticals, The University of
Manchester, UK
REGULATORYLEADERSPANEL
* Conference Proceedings will be conducted in English.
12:50 Networking Lunch & VIP Tables
VIP Table 1 Dr Liu Xiaolin, Vice President of Process
Development, Innovent Biologics, China
VIP Table 2 Dr Ting Xu, CEO, AlphaMab, China
If you would like to be seated on a table with the above guests in an
exclusive lunch setting, please register your interest with
weifang.sim@ibcasia.com.sg. Limited seats are available!
2:30 Control of r-Protein Quality Attributes by Cell Line
Engineering and Media Design
Dr. Nan Lin, Principal Scientist, CHOZN Platform, SAFC, USA
IMPROVING GENE TRANSFECTION
3:00 Targeted Integration of “Hotspots” in CHO Genome for
Rapid Generation of Stable & High Monoclonal Antibody
Producing Cell Lines
We have developed a FRT/FLP based cassette exchange strategy for
efficient targeting of monoclonal antibody (mAb) genes into
predetermined hotspots in the CHO genome. Clones were first generated
by random integration of an optimized tagging vector containing FRT
sequences, a GFP reporter gene, and a stringent selection marker.
Subsequent FACS screening of gene expression level, stability, and
cassette exchange efficiency identified the suitable master clones with
tagged hotspots. The targeting vector was designed to express the
mAb light chain and heavy chain at balanced ratios and optimized for
enhancing the selection stringency of correct cassette exchange. We
have generated master clones which allow generation of stable and
high monoclonal antibody producing cell lines in less than two months.
DrYuanshengYang , Research Scientist, Animal Cell Technology,
Bioprocessing Technology Institute, A*Star, Singapore
3:30 Afternoon Networking & Refreshment Break
4:00 Optimization ofTransient Gene Expression in HEK293 Cells
Polyethylenimine (PEI) mediated transient gene expression has become
a commonly used method for the fast preparation of recombinant
proteins at different scales.The sizes and binding strength between PEI
and DNA molecules are considered the key qualities of PEI/DNA
complexes to accomplish the consecutive events from their cellular
intake to nuclear gene transcription. In electrolytic aqueous media, the
association between PEI and DNA is dynamic and reversible, which may
have a profound impact on process design and medium optimization.
This presentation will discuss the various approaches in increasing the
binding affinity between PEI and DNA and methods in overcoming the
various challenges faced in optimizing PEI mediated transient gene
expression would be discussed
Prof. Bing Q. Shen, Professor, College of Pharmacy, Nankai
University, China
INNOVATIVE TECHNOLOGIES FOR CELL LINE DEVELOPMENT
4:30 Ambr & Ambr250: Systems Enabling High Throughput
Biologics Development
• Introducing the new ambr250 platform
• Novel applications for ambr and ambr250 in consistently predicting
culture behavior at a larger scale
• Overcoming diverse process challenges in eukaryotic or prokaryotic
platforms using the ambr and ambr250 platforms
Ian Ransome, Director, Asia Pacific, TAP Biosystems, UK
5:00 Development of an Automated & Disposable Perfusion
Platform
• Combining two disposable technologies: the CELL-tainer and the
acoustic CytoPerf perfusion system
• Cost effective and automated process control to manage perfusion
• Addressing industrial concerns for perfusion
Gael Peron, Global Director of Sales and Marketing, Charter
Medical, USA
5:30 Chairperson’s Summary of Day One
5:40 Speed Networking & Networking Cocktail
VIP 1 Dr Junhua Qiao, AssociateDirector, Wuxi Apptec, China
VIP 2 Dr Xueming Qian, CEO, Mabspace Biosciences,
China
Exclusive to Registered Participants Only: Limited Spots Available!
Participants have the chance to spend two minutes getting to know
the below key experts in the Biopharma industry! Secure your place
today with weifang.sim@ibcasia.com.sg
7:00 End of Conference Day One
UNPUBLISHEDDATAUNPUBLISHEDDATA

3. C LL LINEC LL LINEC LL LINE
DEVELOPMENT &
ENGINEERING ASIA
CONFERENCE DAY TWO
22 MAY 2014 | THURSTHURSDAY
REGISTERTODAY! +6565082401/+862123263680 register@ibcasia.com.sg www.celllineasia.com
8:55 Chairperson’s Opening Remarks
Dr Wei Kuang Chi, Vice President, Development Centre for
Biotechnology, Taiwan
OPTIMIZING & MODIFYING THE GLYCOSYLATION PROCESS
9:00 Industry Best Practices on Glycosylation Site Control
• Process control strategies for glycosylation site control
• Optimization and prediction of glycosylation site
Sanjeev Gupta, Deputy General Manager – Biosimilars
Development, IPCA Laboratories, India
9:30 CHO Glycosylation Mutants as Potential Hosts to Produce
Therapeutic Antibodies
Proper and consistent glycosylation has long been a major challenge
for the biotech industry. We have generated a panel of VHO
glycosylation mutants from the CHO-K1 cell that can be used to
produce recombinant antibodies with consistent yet unique glycan
structures.These cells can be easily cultured in serum-free media with
growth rates with final cell densities comparable to that of wild type
CHO-K1 cells making them ideal to be used in the biopharmaceutical
industry
Dr Zhi Wei Song, Principal Scientist, Expression Engineering,
Bioprocessing Technology Institute, A*Star, Singapore
10:00 Morning Networking & Refreshment Break
ADVANCES IN CLONE SCREENING/SELECTION
10:30 ReducingTimelines for Generating Recombinant Cell Lines
through Clone Screening & Selection
• Cell line development strategies and protein expression platforms
• Vector design for gene expression and protein production in CHO
cells
• Methods for streamline selection and clonal isolation
• Timeline for cell line development
Dr Noelle-Ann Sunstrom, CEO, Neuclone, Australia
11:00 Accelerating Antibody Process Development: Exploring
the Synergies Between the Use of Engineered Host Cells
and Process Development
James Rance, HeadofDevelopmentServices, LONZA Biologics,
Singapore
COMMERCIALIZING CELL LINES
11:30 From Lab to Commercial Development: Improving the
Manufacturability & Scalability of Mammalian Cell Lines
• What are the key factors that have to be taken into consideration
in scaling up cell lines
• Improving the productivity in a scale up process
• Overcoming the various scale up challenges
David Hughes, CEO, BioPharmaceuticals Australia, Australia
12:00 Networking Luncheon & VIP Lunch Tables
VIP Table 1 Dr H.Fai Poon, Director, Cell Culture,
Hisun Pharmaceuticals, China
VIP Table 2 Dr Zhao (David) Xiao Jian, Senior Vice President
& Chief Technology Officer, Wuhan YZY
Biopharma, China
If you would like to be seated on a table with the above guests
in an exclusive lunch setting, please register your interest with
weifang.sim@ibcasia.com.sg. Limited seats are available!
CELL CULTURE MEDIA DEVELOPMENT
1:30 Do We Need Chemically Defined Media?
• Do we need CD media and process?
• Benefits and disadvantages of developing CD media
• WhatisrequiredtodevelopCDmediaandupstreammanufacturing
process
Dr Shun Luo, President, JS Biosciences, China
2:00 Approaches in Developing Chemically Defined Media
• Identification and optimization of key components
• Case studies on using chemically defined medium to grow cells
of high productivity
• Challenges in developing chemically defined medium and how
to overcome them
Dr Chengbin Wu, Chief Scientific Officer & President of R&D,
Shanghai CP Guojian Pharmaceutical, China
STRATEGIES IN DEVELOPING COMPLEX BIOPRODUCTS
2:30 mAb Cell Line Development Strategies for Biosimilars
• Landscape of mAb biosimilar
• How to define the target mAb molecule for making biosimilars
• Bridging strategies
• Biosimilars: How similar is similar?
• Key consideration for cell line/cell culture development: Similarity,
Stability, Reproducibility and Productivity
Dr. Joe X. Zhou, CEO, Genor BioPharma, China
3:00 Afternoon Networking & Refreshment Break
3:30 Advancements in Developing Complex Biologics from
Mammalian Cell Lines
Complex biologics such as ADCs and bispecifics are an exciting class
of drugs that holds huge potential for the future of therapeutics. This
presentation will discuss the various recent research advancements
that were made in developing various innovative complex biologics
from cell lines, the challenges faced and how were they addressed.
Prof. Peter Gray, Director, Australian Institute of
Biotechnology & Nanotechnology (AIBN), Australia
4:00 Mammalian vs Non-Mammalian Cell Line Development
Platforms
• Challenges and benefits in developing bioproducts from various
cell line development platforms
• Comparison of safety, cost and quality of non-mammalian cell
lines and mammalian cell lines
• Future trends in moving away from CHO cell lines
Moderator:
Dr Jianguo Yang, Principal Scientist, Genzyme/Sanofi, USA
Panelists:
Dr Wei Kuang Chi, Vice President, Development Centre for
Biotechnology, Taiwan
Dr H.Fai Poon, Director, Cell Culture, Hisun Pharmaceuticals,
China
Dr Ting Xu, CEO, AlphaMab, China
ROUND TABLE DISCUSSIONS
4:40 Round Table Discussions
1. New Cell Culture Platform Technology for Biosimilar
and Biobetter
Dr H.Fai Poon, Director, Cell Culture,
Hisun Pharmaceuticals, China
2. ADC, Multispecifc and Fc Modification, How Does
Cell Culture Help?
Dr Zhao (David) Xiao Jian, SVP & CTO,
Wuhan YZY Biopharm, China
3. Selection and Stability Research on Cell Lline
Prof. Peter Gray, Director, Australian Institute of
Biotechnology & Nanotechnology (AIBN), Australia
4. Clone Selection Platforms and Future possibilities
Dr Junhua Qiao, Associate Director, Wuxi Apptec, China
Limited Seats Are Available! Secure your place with
weifang.sim@ibcasia.com.sg
5:30 Chairperson’s Summary of the Day & End of Conference
UNPUBLISHEDDATA
PANELDISCUSSION
UNPUBLISHEDDATA

4. C LL LINEC LL LINEC LL LINE
DEVELOPMENT &
ENGINEERING ASIA
WORKSHOPS
REGISTERTODAY! +6565082401/+862123263680 register@ibcasia.com.sg www.celllineasia.com
Pre-Conference Workshop A: 20 May 2014 (0900-1230)
Optimizing Cell Culture Media Development & Design Strategies
About Your Workshop Leader:
Dr Zhao (David) Xiao Jian, Senior Vice President & Chief Technology Officer, Wuhan YZY Biopharma, China
Dr Zhao completed his doctorate in Biochemistry at Colorado State University in 1994. After his post-doctoral researches at University of Colorado
and the Southeast Blood Research Institute atWisconsin, he joined Amersham Pharmacia in 1998 as a scientist working on microarray technologies.
He worked as the group leader and Sr. scientist at Orchid Bioscience, the director of development at US genomics, R&D director at Invitrogen,
and the director of cell culture at EMD Millipore-a division of Merck A/G, CSO and board member of Yison bioscience. As CTO and Sr. VP of YZY
biopharma at Wuhan, he is currently responsible for antibody therapeutic development and manufacturing. Dr. Zhao has developed many
technologies and products during his career.
Cell Banking Management
Maintaining a cell bank to preserve these cell lines is no
simple task. Various factors have to be taken into
consideration and maintained such as quality, safety,
stability, productivity, preservation as well as ensuring
that the cell bank is free from contamination. This
workshop aims to introduce the various aspects of cell
banking.
Sanjeev Gupta has a Masters in Applied Microbiology & Biotechnology and is pursuing his Ph.D. in Microbial biotechnology. He has over 13 years
of industrial experience and has been working in development of recombinant therapeutic proteins & monoclonal antibodies (Biosimilars). So
far, he developed and delivered over 10 recombinant clones of which three Biosimilar products has been launched already in the Indian market
and the rest is in developmental or clinical phase, and expected to be launched soon. He also has experience in developing the human antibody
gene library in unique and novel expression platform. During his professional tenure, he worked at various positions in reputed Indian
biopharmaceuticals industries such as Zydus Cadila, Wockhardt Research, Panacea Biotech, Intas Biopharmaceuticals.
Cell culture media plays a huge role in the success of
cell development. Being able to develop a high-quality
media which is able to give reproducible results and
high yields can contribute significantly to the cost,
scalability, process robustness as well as the time to
market. This workshop will provide attendees a strong
foundation of cell culture media development,
optimization and feed strategies.
Pre-Conference Workshop B: 20 May 2014 (1330-1700)
Topics To Be Discussed Include:
• Introduction to the Master Cell Bank (MCB) and Working Cell Bank (WCB)
• Regulations surrounding cell banking
• GMP cell banking
• Ensuring the authenticity of cell banks
• Analytical characterization procedures: Tests for identification, purity and stability
• Best practices in contamination control
• Bio-preservation methods: What are available and how to select the optimal method
• Cell bank storage
About Your Workshop Leaders:
Sanjeev Gupta, Deputy General Manager – Biosimilars Development, IPCA Laboratories, India
Dr Cheng Zhang, CSO/CTO, Gmax Biopharm, China
Dr Cheng Zhang is the CSO/CTO of Gmax Biopharm, he has two decades of working experiences in the biomedical field including NIH and three
biopharmaceutical companies (Hybridon, Millennium and Amgen) in the United States. He has multi-year working experiences in both small-
molecule and antibody drug development, and is an experienced expert in therapeutic antibody discovery and development.
The Road to Commercialization: From Cell to Market
Post-Conference Workshop C: 23 May 2014 (0900-1700)
Getting your innovative biologics into the competitive
biopharmaceuticals market requires thorough planning
and a good strategy to ensure commercial success. This
workshop aims to introduce participants to the
commercial aspects of R&D and how to ensure their
product launch to market whether it is a launch of a
new commercial cell line or new innovative biologic.
Topics To Be Discussed Include:
• Risks involved in cell line development
• Cost-cutting measures that can be undertaken
• What does it takes to launch a new commercial cell line into the market
• Labour issues in hiring and retaining the right talents
• Product pipelines strategies
• Creating a business plan for a successful product launch
Dr Zhongling Feng, CSO and Vice President, Viropro, USA
Topics To Be Discussed Include:
• Tips in designing and developing your ideal culture media that is best suited to your systems
• Strategies to develop the cell culture media fast and efficiently
• Determining the optimal conditions: Chemical and physiological conditions
• What are the High throughput (HT) technologies available?
• Case studies on how cell media affects cell culture results
• Tips in selecting the right cell culture processes: Batch fed or perfusion
• Approaches in designing feeding strategies for high yield and high quality products
• Case studies on different feeding strategies
About Your Workshop Leader:
Dr. Zhongling Feng is Vice President and Chief Scientific Officer of Viropro, Inc. and has more than 15 years of experience in conducting basic and
industrial research focused on discovering new therapies for globally important diseases. He received his M.D. and Ph.D. degree from China Medical
University with residency training in radiation therapy. He completed post-doctoral training at Center for Biochemical and Biophysical Sciences
and Medicine at Harvard Medical School and Department of Medicine at Brigham and Women's Hospital. He is an inventor on two patents, has
14 scientific publications and serves on the editorial board of World Journal of Stem Cells. Dr. Feng is currently responsible for leading the
development and commercialization strategy to market approach for several biosimilars such as Rituximab and human biosimilar insulins at
Viropro, Inc. In addition, he is leading to license many inventions and technologies for commercialization through external partnerships.

5. REGISTERTODAY! +6565082401/+862123263680 register@ibcasia.com.sg www.celllineasia.com
BY INDUSTRY:
■ Pharmaceuticals/Biotechnology: 50%
■ Research Institutes/Universities: 10%
■ CMOs: 20%
■ CROs: 10%
■ Technology Providers: 10%
BY REGION:
■ China, Taiwan, Hong Kong: 60%
■ Japan, Korea: 10%
■ Rest of Asia: 10%
■ Europe: 10%
■ USA: 5%
■ Australia: 5%
Roche Diagnostics • Boehringer-Ingelheim • Genzyme • Sanofi • Shanghai Henlius Biotech • Eureka Therapeutics • Simcere • Luye Pharma • BTI A*Star •
Neuclone •WuhanYZY biopharma •Wuxi apptec • Fountain Biopharma • Novo Nordisk • Harbin Pharmaceutical Group • Genor Biopharma •TTY Biopharm
company • JS Biosciences • Hisun Medicine • Genloci Biotechnologies • Shanghai Jiaotong University • University of Queensland • University of
Manchester • Swiss Institute of Technology • John Hopkins University School of Medicine • National Health Research Institutes • Autekbio • Genescience
• Dragonfly Sciences • Eli Lilly and Company • Hengru Medicine • TPG Biologics • Sinocelltech • Jiangsu Henrui Medicine • Egret Pharma Shanghai •
Beijing Mabworks Biotech • Cbiopharm • Japan Asia Inestment (China) • 3SBIO • Jiangsu T-Mab Biopharma • SG Austria • Lonza Biologics • Tap biosystems
• Sigma-Alrich • Genscript China • GE Healthcare AND MANY MORE...
Snapshot of Past Attending Companies Include:
The global cell culture market is expected to reach USD 16.85 billion
globally in 2018 (Transparency Market Research, 2013). However,
the development of cell lines is still plagued with many challenges
including quality, cost, timelines in the cell line development process,
as well as titer. Due to the high cost of biologics production,
strategies for cost-effective cell line development solutions to hasten
the drug into the market can ultimately lead to high profit margins.
IBC’s Cell Line Development & Engineering Asia brings together
top experts and scientists from biopharma, biotechs, research
institutes, universities, CMOs and CROs as well as leading technology
solutions providers from all over Asia and the rest of the world.
It provides a platform where industry and research experts can
share research developments, case studies, best practices and
discuss challenges pertaining to the cell line development industry
to increase the efficacy and quality of cell lines for a faster, safer
and more efficient biologics development process.
The Biopharma Development & Production Week is the leading
industry platform for pharma, biotech, CMOs, CROs, research institutes,
investors and industry stakeholders to meet, network and discuss
current industry trends, establish business partnerships and be
updated on investment opportunities in China and surrounding Asia.
Co-Located with:
• Showcase the latest technology
• Meet & Network with senior decision makers in Asia
• Position your brand as the market leader to stand out amidst competition
• Generate new business contacts and strengthen existing accounts
LIMITED SPONSORSHIP & EXHIBITION OPPORTUNITIES AVAILABLE:
Do you provide innovative technology to support cell line development in Asia?
For sponsorship opportunities,
contact Yvonne Leong at
Tel: +65 6508 2489
Email: yvonne.leong@ibcasia.com.sg
Who Should Attend:
Abundant Networking Opportunities with
Regional & Global Companies!
BIOBIO
MANUFACTURING
BIOSIMILARSSIMILARSSIMILARSBIBI
ASIA
BI
www.biosimilarsasia.com www.biomanufacturing-asia.com
About the BDP Week
Grow & Benchmark
Your Company Profile
in the Cell Line Industry
Meet VIP
Guests at
Networking
Luncheons
Exchange Business
Cards & Get to Know
Your Peers in the
Shared Morning Ice
Breaker
Speed Networking
with Pharmaceutical &
Biotechnology
Companies
Shared Networking
Breaks & Exhibition
Build Lasting
Partnerships &
Networks in a Casual
Networking
Evening Cocktail
20 — 23 May 2014
Grand Hyatt Shanghai, China
Accelerating Your Cell Line Development with Efficacy & Quality
Part of
PRODUCTION
BIOPHARMA
DEVELOPMENT &
WEEK
C LL LINEC LL LINEC LL LINE
DEVELOPMENT &
ENGINEERING ASIA
3RD ANNUAL

6. GROUP BONUS: REGISTER 3 DELEGATES FROM THE SAME COMPANY AND THE 4TH ATTENDS FOR FREE!
CREDIT CARD PAYMENTS
The best way to pay by credit card is through our secure on-line registration process, simply log on to the website at www.celllineasia.com
and click “Register On-line”. If you would prefer to pay over the phone please complete the contact name and details and our Customer
Services Team will call within 24 hours to take payment. As we treat your credit card information in the strictest confidence, please do not
send payment details by email.
Credit card contact: Department:
Direct phone number: Email:
Grand Hyatt Shanghai, China
Jin Mao Tower, 88 Century Boulevard
Pudong, Shanghai 200121
Tel: +86 21 5049 1234 | Fax: +86 21 5049 8381
Contact Person: Judy Xu
Email: judy.xu@hyatt.com
ENJOY SUBSTANTIAL SAVINGS WITH
OUR MULTIPLE BOOKING DISCOUNT!
Early Bird Rate
Register & pay on or
before 14 Mar 2014
FEE PER DELEGATE Special Rate
Register & pay before
11 Apr 2014
Group Rate
(3 or more delegates)
Normal Rate
Register & pay after
11 Apr 2014
111 Somerset Road,
TripleOne Somerset #10-06, Singapore 238164
Tel: +65 6508 2400 Fax: +65 6508 2408
REGISTER NOW! FAX BACK TO +65 6508 2407
HOTEL INFORMATION
DATA PROTECTION
PAYMENT TERMS
CANCELLATION / SUBSTITUTION
IMPORTANT NOTE
This label contains your priority booking code. To expedite registration, please do not remove label. If you have
already received a copy of this brochure, we apologise. For reasons of confidentiality, your full particulars were not
available to IBC Asia (S) Pte Ltd for deduplication prior to mail drop.
6 EASY WAYS TO REGISTER
REGNO.200108203N
3rd CELL LINE DEVELOPMENT & ENGINEERING ASIA
RESERVE YOUR PLACE TODAY!
P46237
USD 2,695 USD 2,895 USD 2,995 USD 2,495
If undelivered, please return to:
MAIL the attached registration form with
your cheque to IBC Asia (S) Pte Ltd
c/o Informa Regional Business
Services
111 Somerset Road, TripleOne
Somerset #10-06, Singapore 238164
Email
register@ibcasia.com.sg
Fax
+65 6508 2407
Web
www.celllineasia.com
SAVE WITH THE
EARLY BIRD &
SPECIAL RATES!
Scan the QR Code
with your smartphone
and register today
The personal information entered during your registration/order, or
provided by you, will be held on a database and may be shared
with companies in the Informa Group in the UK and internationally.
Occasionally, your details may be obtained from or shared with
external companies who wish to communicate with you offers
related to your business activities. If you do not wish your details
to be used for this purpose, please contact our Database Department
at Email: database@ibcasia.com.sg, Tel: +65 6508 2400 or
Fax: +65 6508 2408.
Should you be unable to attend, a substitute delegate is welcome
at no extra charge. Cancellations must be received in writing at
least 10 business days before the start of the event, to receive a
refund less 10% processing fee per registration. The company
regrets that no refund will be made available for cancellation
notifications received less than 10 business days before the event.
Please quote the name of the delegate, event title and invoice
number on the advice when remitting payment. Bank charges are
to be deducted from participating organisations own accounts.
Please fax your payment details (copy of remittance advice, cheque
or draft to +65 6508 2407).
Attendance will only be permitted upon receipt of full payment.
Participants wishing to register at the door are responsible to ensure
all details are as published. IBC assumes no further liability or
obligation, beyond the refund of the paid registration fee, in the
event of postponement or cancellation by IBC.
❑ Yes! I/We will attend the 3rd Cell Line Development & Engineering Asia
20 – 23 May 2014, Grand Hyatt Shanghai, China
❑ I would like to purchase the conference presentations
at SGD1000 + GST (SGD1070) per log in.
Payment must be received 10 business days prior to the event.
To take advantage of discounts with an expiry cut-off date,
registration and payment must be received by the cut-off date.
All payments should be made in US or CNY dollars.
• Payments by US$ bank draft or cheque should be made in
favour of “IBC Asia (S) Pte Ltd” and mailed to:
IBC Asia (S) Pte Ltd
c/o Informa Regional Business Services
111 Somerset Road, TripleOne Somerset #10-06,
Singapore 238164
Attn: The Accounts Receivable Team
• Payment by telegraphic transfer in US$ must be made to:
IBC Asia (S) Pte Ltd
A/C No.: 260-457866-178 (USD)
The Hongkong and Shanghai Banking Corporation Limited,
21 Collyer Quay, HSBC Building, Singapore 049320
Bank Swift Code: HSBCSGSG
Bank Code: 7232
• Payment by telegraphic transfer in CNY must be made to:
A/C Name:
Conferences and Event Management Services (Shanghai)
Co., Ltd.
A/C No.: 720-031103-001
Beneficiary Bank:
Bank (China) Company Limited
Bank Address: No. 1000 Lujiazui Rind Road, Pudong, Shanghai
200120, P.R. China
• Payment by credit card in US$ (AMEX, VISA or MasterCard)
The best way to pay by credit card is through our secure portal
built into the website. To pay by phone please indicate the
contact name and details below and our Customer Services
Team will call within 24 hours to take payment. Please do not
send credit card information by email.
HSBC
IBC
USD 2,495 USD 2,695 USD 2,795 USD 2,295
USD 2,295 USD 2,495 USD 2,595 USD 2,095
International Companies
USD 1,995 USD 2,195 USD 2,295 USD 1,795
USD 1,695 USD 1,895 USD 1,995 USD 1,495
China Domestic Companies
CNY 6,500 CNY 7,500 CNY 8,000 CNY 6,000
CNY 6,000 CNY 7,000 CNY 7,500 CNY 5,500
CNY 5,500 CNY 6,500 CNY 7,000 CNY 5,000
CNY 5,000 CNY 6,000 CNY 6,500 CNY 4,500
CNY 4,500 CNY 5,500 CNY 6,000 CNY 4,000
Who is Head of your Department?
Who is Head of Training?
Company Information
Company Name:
Address:
Main Business/Activity:
Postal Code:
Please photocopy for additional delegates
FREE
GROUP DISCOUNT
Delegate 1 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 2 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 3 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
Delegate 4 Details
Name: Dr/Mr/Ms
Job Title:
Department
Tel:
Mobile No.:
Email:
• Multiple Bookings Discount pricing is applicable to groups of 3 or more delegates from the same organisation registering for the same event, at the same time. Fee stated
is the discounted price PER DELEGATE. Only one discount applies; either the early bird rate OR special rate OR group rate.
• All fees stated include luncheons, refreshments and complete set of documentation. It does not include the cost of accommodation and travel.
• Registration fees are subject to the prevailing government tax
International companies have Global Headquarters located outside mainland China. A China domestic company has its global headquarters located
within mainland China. Regulatory Authorities, Government and Academia will be accorded 40% off Normal Rates
Payment Method (Please tick:) ❑ I enclose my bankers draft / cheque payable to IBC Asia (S) Pte Ltd
❑ I am paying by bank transfer (copy attached)
❑ Payment by Credit Card. (AMEX, VISA or MasterCard accepted)
Customer Service Hotline
+65 6508 2401 [Singapore]
+86 21 2326 3680 [China]
❑ 4 Days Package - 2 Day Conference + All
Workshops (A+B+C)
❑ 3.5 Days Package - 2 Day Conference +
Workshops (A or B + C)
❑ 3 Days Package - 2 Day Conference +
Workshops (A+B or C)
❑ 2.5 Days Package - 2 Day Conference +
Workshop (A or B)
❑ 2 Day Package - 2 Day Conference only
❑ 4 Days Package - 2 Day Conference + All
Workshops (A+B+C)
❑ 3.5 Days Package - 2 Day Conference +
Workshops (A or B + C)
❑ 3 Days Package - 2 Day Conference +
Workshops (A+B or C)
❑ 2.5 Days Package - 2 Day Conference +
Workshop (A or B)
❑ 2 Day Package - 2 Day Conference only